Moonlake Immunotherapeutics (MLTX) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Moonlake Immunotherapeutics  (NASDAQ: MLTX)


Moonlake Immunotherapeutics's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Moonlake Immunotherapeutics's ROI in the second quarter of 2026?
Moonlake Immunotherapeutics recorded a cumulative net loss of $-265 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -65.15%.

Within the Healthcare sector 14 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3208 to 3776.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -13.98 % -23.08 % -19.17 % -17.91 % -13.63 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 529 353 379 368 436
Return On Investment (TTM) -65.15 % -67.58 % -55.05 % -48.65 % -37.85 %
MLTX's Overall Ranking # 3776 # 3208 # 2108 # 3461 # 2931
Seq. Investment Change TTM 6.02 % -8.23 % -4.75 % -7.17 % -5.2 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -265 -259 -230 -214 -179

MLTX Company Profile >> Back to MLTX Roi Comparisons >> See Annual MLTX Return On Investment



Return On Investment MLTX's Ranking
Within: No.
Industry # 4
Sector # 15
Overall # 3776

Return On Investment Statistics
High Average Low
-2.92 %
-33.45 %
-73.81 %
(Mar 31 2022)   (Mar 31 2023)







Financial Statements
Moonlake Immunotherapeutics's II. Quarter Investments $ 529 Millions MLTX's Balance sheet
Moonlake Immunotherapeutics's II. Quarter Income $ -62 Millions Quarterly MLTX's Income Statement
MLTX's Income by Division See MLTX's Income by Division


MLTX Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 379 462 532 89 112
Y / Y Investment Growth -18.06 % -13.13 % 498.18 % -20.59 % -3.9 %
Net Income in Millions -230 -121 -44 -65 -5
Y / Y Net Income Growth - - - - -
Annual Return On Investment -60.84 % -26.24 % -8.29 % -72.55 % -4.06 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
MLTX's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for MLTX's Competitors
Subscribers only: Roi for Moonlake Immunotherapeutics's Suppliers
Subscribers only: Return On Investment for MLTX's Customers

Other Ratios
MLTX's Roa MLTX's Inventory Turnover Ratio MLTX's Growth Rates MLTX's Dividend Statistics
MLTX's Profitability Ratios MLTX's Asset Turnover Ratio MLTX's Dividend Growth
MLTX's Roe MLTX's Valuation Ratios MLTX's Financial Strength Ratios MLTX's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:40:22+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.